Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group.

Trial Profile

Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Nov 2013

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Breast cancer; Cancer; Gastric cancer; Malignant ascites; Ovarian cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 Jun 2012 Quality-of-life results published in the Annals of Oncology.
    • 27 Sep 2011 Quality-of-life results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 07 Jun 2011 Overall survival outcomes according to lymphocyte counts were presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top